Summary of Alaunos Therapeutics Q1 2023 Earnings Call

1Key Financial Results and Metrics

Net Loss: $10 million, or $0.04 per share, compared to a net loss of $9.8 million, or $0.05 per share, in Q1 2022.

R&D Expenses: Approximately $6.5 million, up 17% from $5.6 million in Q1 2022, primarily due to increased manufacturing and TCR discovery activities.

General and Administrative Expenses: Approximately $3.2 million, down 10% from $3.5 million in the prior year, attributed to lower professional fees.

Cash Position: $37.4 million in total cash balances as of March 31, 2023, with an operating cash burn of approximately $9.4 million for the quarter.

Cash Runway: Expected to last into Q4 2023, with projected operating cash outflows for the year between $35 million and $40 million.

2Strategic Updates and Business Highlights

Clinical Progress: Accelerated enrollment in the TCR-T library Phase 1/2 trial, with enhancements to screening and manufacturing processes, including the introduction of cryopreservation.

Partnerships and Licensing: Amended agreement with Precigen to eliminate royalty and milestone obligations, potentially saving over $160 million, while maintaining exclusive rights to TCRs targeting neoantigens.

Hunter Platform: Expansion of the proprietary TCR discovery platform, aiming to increase the number of TCRs from 12 to 15, enhancing the addressable market for therapies.

Manufacturing Capacity: Significant improvements in manufacturing capabilities, with plans to further expand capacity for Phase 2 trials.

3Forward Guidance and Outlook

Interim Results: Expected to report interim results in Q3 2023, including data from multiple patients treated in the Phase 1 portion of the trial.

Patient Enrollment: Anticipating treatment of 9 to 12 patients by year-end to complete the Phase 1 study, with ongoing engagement from principal investigators.

Future Developments: Continued focus on advancing the TCR platform and exploring partnerships for non-dilutive funding opportunities.

4Bad News, Challenges, or Points of Concern

Cash Burn Increase: Operating cash burn increased from $7.8 million in Q1 2022 to $9.4 million in Q1 2023, raising concerns about financial sustainability as the company approaches its cash runway limit.

Interim Data Dependency: The upcoming interim data release in Q3 is critical for future financing, raising stakes for the company’s financial health and investor confidence.

Enrollment Targets: Although the company maintains that the target of 12 to 15 patients remains unchanged, the current guidance of 9 to 12 patients for the Phase 1 trial may indicate potential challenges in patient recruitment.

5Notable Q&A Insights

ASCO Presentation: The company will present translational data for the first three patients at the ASCO Annual Meeting, but specifics are limited until the embargo lifts on May 25.

Enrollment Clarification: Management confirmed that the patient count for the Phase 1 trial aligns with previous guidance, with no change in target despite initial concerns.

Cash Runway Confidence: Management expressed confidence that the interim update will be positively received, and they are exploring all financing avenues while being cautious about dilution.

Manufacturing Capacity for Phase 2: Plans for a multipronged manufacturing strategy are in place to meet the increased demands of Phase 2 trials, with flexibility in scaling operations. This summary encapsulates the key points from the earnings call, providing a balanced view of Alaunos Therapeutics' current financial health, strategic initiatives, and potential challenges ahead.